Oncology Company Announces FDA Clearance For Cancer Treatment Study

Notable Labs, Ltd. (Nasdaq: NTBL) has recently announced a pivotal development in its clinical-stage journey. The company, known for its innovative Predictive Medicine Platform (PMP), disclosed that it has received the coveted "Clearance to Proceed" from the FDA for its Phase 2 volasertib program. A crucial step forward in the pursuit of novel cancer therapies, particularly focusing on relapsed refractory acute myeloid leukemia (R/R AML). The Phase 2 volasertib program, designed to evaluate the efficacy of volasertib in combination with decitabine for patients with R/R AML, has garnered enthusiastic responses from key figures within Notable Labs. Thomas Bock, M.D., the Chief Executive Officer, expressed optimism about the progress made, emphasizing the urgent need for effective treatments in the realm of AML. With the FDA clearance and a defined dosing plan in place, Notable is poised to commence enrollment for the Phase 2 study in the near future. $Notable Labs (NTBL.US)$